Advertisement

Opthea Limited OPT

Set alert

Price alert · OPT

All alert types
3.41 0.00 0.00%

At close · Apr 1

3.41 Day range 3.41
1.79 52-week range 5.45
Open
3.41
Prev close
3.41
Mkt cap
571.73M
Vol
3.02K
Avg vol
28.93K
EPS
-2.76
P/E
0.00
Div yield
0.00%
More statistics
Low
3.41
High
3.41
Forward P/E
-1.95
Beta
1.54
Short ratio
2.45
Inst. own
3.57%
Dividend
0.00
Ex-div date
Earnings
Aug 29, 2024
50-d avg
3.91
200-d avg
3.26
1y target
12.17

1Y chart

Chart tools
Interval

Events in this range
  • Aug 29, 2024Earnings: —; estimate 0; surprise —%
  • Sep 3, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (45)
NameDateAgo
MACD: Buy SignalMar 24, 20251 year ago
SMA: BearishMar 4, 20251 year ago
MACD: Sell SignalFeb 12, 20251 year ago
RSI: OverboughtFeb 5, 20251 year ago
RSI: OverboughtJan 28, 20251 year ago
RSI: OverboughtJan 24, 20251 year ago
SMA: BullishJan 16, 20251 year ago
SMA: BearishJan 15, 20251 year ago
SMA: BullishJan 14, 20251 year ago
SMA: BearishJan 10, 20251 year ago
SMA: BullishJan 7, 20251 year ago
SMA: BearishJan 6, 20251 year ago
SMA: BullishJan 3, 20251 year ago
SMA: BearishJan 2, 20251 year ago
SMA: BullishDec 27, 20241 year ago
MACD: Buy SignalDec 23, 20241 year ago
SMA: BullishDec 20, 20241 year ago
SMA: BearishDec 17, 20241 year ago
MACD: Sell SignalDec 17, 20241 year ago
SMA: BullishDec 16, 20241 year ago
SMA: BearishDec 13, 20241 year ago
MACD: Buy SignalNov 29, 20241 year ago
SMA: BullishNov 26, 20241 year ago
SMA: BearishNov 21, 20241 year ago
RSI: OversoldNov 14, 20241 year ago
SMA: BearishNov 12, 20241 year ago
SMA: BullishNov 8, 20241 year ago
SMA: BearishNov 7, 20241 year ago
MACD: Sell SignalOct 18, 20242 years ago
RSI: OverboughtSep 16, 20242 years ago
MACD: Buy SignalSep 9, 20242 years ago
MACD: Sell SignalSep 6, 20242 years ago
RSI: OverboughtAug 28, 20242 years ago
RSI: OverboughtAug 26, 20242 years ago
SMA: BullishAug 21, 20242 years ago
RSI: OverboughtAug 21, 20242 years ago
RSI: OverboughtAug 19, 20242 years ago
SMA: BullishAug 9, 20242 years ago
MACD: Buy SignalJul 2, 20242 years ago
SMA: BearishJun 3, 20242 years ago
RSI: OversoldJun 3, 20242 years ago
RSI: OversoldMay 30, 20242 years ago
MACD: Sell SignalMay 21, 20242 years ago
SMA: BullishMay 9, 20242 years ago
MACD: Buy SignalMay 9, 20242 years ago

Key statistics

Market cap
571.73M
Enterprise value
4.14B
Trailing P/E
0.00
Forward P/E
-1.95
PEG ratio
0.00
Price / sales
2183.37
Price / book
0.00
EPS (TTM)
-2.76
Beta
1.54
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
261.86K
Revenue growth
-68.30%
Free cash flow
-94.87M
Total cash
172.47M
Total debt
200.63M
Return on equity
0.00%
Shares outstanding
153.89M
Short % of float
0.06%
50-day average
3.91
200-day average
3.26

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 12.17 +256.8% upside
Target (low)
8.00
Target (mean)
12.17
Target (high)
18.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy5
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 29, 2024

Expected Aug 29, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
OPT Revenue — annual 146.00K
2019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
OPT Net income — annual -162.79M
2019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
OPT EPS — annual -1.06
2019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025

Earnings

OPT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 29, 2024Jun 1, 20240.00———
Sep 12, 2023Jun 1, 2023-1.28———
Aug 29, 2022Jun 1, 20220.00———

Upgrades / downgrades

OPT analyst upgrades and downgrades
DateFirmActionFromTo
Sep 3, 2024HC Wainwright & Co.mainBuyBuy
Sep 13, 2023OppenheimermainOutperformOutperform
Aug 1, 2023HC Wainwright & Co.reitBuyBuy
May 16, 2023EF HuttonreitBuyBuy
Apr 17, 2023EF Huttoninit—Buy
Mar 13, 2023Oppenheimermain—Outperform

About Opthea Limited

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.

Sector
Healthcare
Industry
Biotechnology
Country
Australia
Website
opthea.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on OPT — it syncs with the Stock Master app.

Institution ownership

OPT institution ownership
Holder% heldSharesValueReported
Regal Partners Ltd.5.40%2,907,40310.49MSep 29, 2024
Baker Bros. Advisors, LP4.04%2,173,6227.84MSep 29, 2024
Millennium Management Llc0.13%67,392243.18KSep 29, 2024
Stratos Wealth Partners, Ltd.0.05%29,600106.81KSep 29, 2024
Jane Street Group, LLC0.05%26,63296.10KSep 29, 2024
Twin Lakes Capital Management, LLC0.04%19,80671.47KSep 29, 2024

Fund ownership

OPT fund ownership
Holder% heldSharesValueReported
USAA Mutual Fund Tr-Science & Technology Fund0.46%247,678893.75KJul 30, 2024
Fidelity NASDAQ Composite Index Fund0.01%5,04918.22KOct 30, 2024
Advertisement